SCHEMBL1396282

SCHEMBL1396282

CCOC(=O)N(N)c1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KMT2A Q03164 2/20 0.49
ABCC1 P33527 1/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
CYP3A4 P08684 2/20 0.44
ABCB11 O95342 1/20 0.44
CYP1A2 P05177 1/20 0.44
TSHR P16473 1/20 0.44
HTR2A P28223 1/20 0.44
PMP22 Q01453 1/20 0.44
PPARA Q07869 1/20 0.44
HPGD P15428 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5087384 0.86 MAOB (0.53) CYP3A4
SCHEMBL1396326 0.86 RAB9A (0.46) ALDH1A1KMT2APOLBSMN1; SMN2CYP3A4
SCHEMBL11142995 0.86 ALDH1A1 (0.51) ALDH1A1KMT2AABCC1POLBSMN1; SMN2
SCHEMBL6426131 0.85 MAPT (0.62) ALDH1A1KMT2APOLBSMN1; SMN2CYP1A2
SCHEMBL10790625 0.84 LMNA (0.53) ALDH1A1KMT2ASMN1; SMN2CYP3A4CYP1A2
SCHEMBL1396267 0.82 ALDH1A1 (0.52) ALDH1A1KMT2APOLBSMN1; SMN2CYP3A4
P-Xylene SCHEMBL8521620 0.81 ALDH1A1 (0.48) ALDH1A1KMT2APOLBSMN1; SMN2CYP3A4
SCHEMBL9357885 0.81 CHRNB2 (0.61) ALDH1A1KMT2AABCC1POLBSMN1; SMN2
SCHEMBL5096534 0.79 MAOB (0.48) ALDH1A1KMT2APOLBCYP3A4PPARA
SCHEMBL23632078 0.79 KMT2A (0.45) ALDH1A1KMT2APOLBSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2288612-B1 GABAA RECEPTOR MODULATORS GABATHER AB (SE) 2015-07-29 EP disclosed
US-8809355-B2 GABAA receptor modulators INNOVATIONSPATENT SVERIGE AB (SE) 2014-08-19 US disclosed
US-20110092525-A1 GABAA RECEPTOR MODULATORS GABATHER AB (SE) 2011-04-21 US disclosed
EP-2288612-A1 GABAA RECEPTOR MODULATORS Forskarpatent i Syd AB (SE) 2011-03-02 EP disclosed
WO-2009123537-A1 GABAa RECEPTOR MODULATORS FORSKARPATENT I SYD AB (SE) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092525-A1 GABAA RECEPTOR MODULATORS GABRA5, GABRA1, GABRA2 ALDH1A1 716/4885KMT2A 1156/4885ABCC1 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.